Breast Cancer Research

Table 7 Association of PD-L1 staining with estrogen receptor/progesterone receptor-positive and triple-negative status in sTIL subgroups in patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

	TC				TCIC				IC
	sTIL < 10%		sTIL ≥10%		sTIL < 10%		sTIL ≥10%		sTIL < 10%		sTIL ≥10%
PD-L1	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
ER/PR pos	195	10	26	13	188	17	17	22	195	10	18	21
TNBC	21	0	32	6	21	0	20	18	21	0	20	18
Fisher P value	0.6044		0.1121		0.3787		0.4917		0.6044		0.6509

ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, sTIL stromal tumor infiltrating lymphocytes, pos positive, neg negative

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com